Product & Capacity
Our cutting-edge facility boasts a formidable production capacity, reinforcing our commitment to meeting global healthcare needs. We are proud to announce the capability to fill approximately 9.0 million vials and lyophilize about 1.2 million vials, setting the stage for the mass production of life-saving vaccines.
Flagship Products:Dow Rab - Registered Rabies Vaccine
Dow Rab stands as our flagship product, a Registered Rabies Vaccine crafted through inactivated lyophilized technology. With a potency exceeding 2.5 international units per dose and developed using Vero cell technology, Dow Rab exemplifies our dedication to producing high-quality vaccines to combat the threat of rabies.
Our commitment to public health extends to addressing the dangers posed by snakebites. Dow ASV, our Anti Snake Venom, is meticulously crafted to counteract the effects of snake venom. Currently, the product dossier has been submitted to regulators, and we eagerly await their approval to bring this essential life-saving solution to those in need.
In addition to our proprietary vaccines, Dow Institute of Life Sciences extends its expertise through third-party manufacturing collaborations. We offer our advanced production capabilities to partners seeking high-quality, reliable manufacturing services for a variety of life sciences products. Trust us as your manufacturing partner, and together, we can contribute to a healthier, safer world.
Our facility is equipped to handle large-scale production, ensuring a steady supply of vaccines to meet global demands.
Our commitment to innovation is reflected in our use of advanced technologies such as lyophilization and Vero cell culture.
From rabies vaccines to anti-snake venom, our range of products showcases our versatility and dedication to addressing diverse healthcare challenges.